HealthTech180
  • Home
  • Activities
  • Our Team
  • Contact Us
Select Page

Azitra brings in $14m Series A to advance microbiome skin therapies

by admin | Oct 28, 2019 | Funding

Connecticut-based microbiome therapy company Azitra recently announced a $14 million haul in Series A funding. The round was led by KdT Ventures and previous investor Bios Partners, along with Godfrey Capital and Connecticut Innovations. Azitra, which focuses on...

SurgiMab – Phase 3 Trial Evaluating a Novel Fluorescent Tumor-specific Antibody for the Improvement of Surgical Outcomes in Colorectal Cancer Patients

by admin | Oct 28, 2019 | Clinical Trials

SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, announces that the first US patient has been recruited into its on-going pivotal Phase...

Chugai Renews License to EpiVax’s ISPRI In Silico Toolkit for Immunogenicity Assessment

by admin | Oct 28, 2019 | Licensing

Chugai, one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products, integrated the advanced ISPRI toolkit into their preclinical assessment pipeline after an extended head-to-head comparison with other in silico tools...
« Older Entries
Next Entries »
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.

Categories

Follow Us

Tags

AI Alzheimer antibodies Azitra Bioeq Biosimilar Cancer cardiovascular cell therapy CE Mark clinical trial Diagnostics Digital Health Distribution Drug Discovery Enterome EpiVax' FDA FDA approval funding fundraising HIV Immunogenicity Immunotherapies Licensing M&A medical device microbiome Neuro next-gen sequencing PathAI pathology Pepticom pharma RNA robots Shape Therapeutics skin software SurgiMab Therapeutics therapies USA VIrology Virus

Home
Activities
Our Team
Contact Us

 contact@healthtech180.com

Privacy Policy

© 2022 HealthTech180 Advisory S.L.